Biosyent Inc
XTSX:RX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biosyent Inc
Depreciation & Amortization
Biosyent Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosyent Inc
XTSX:RX
|
Depreciation & Amortization
-CA$862.4k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-46%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Depreciation & Amortization
-$1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Depreciation & Amortization
-CA$51.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Depreciation & Amortization
-$2.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-37%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Depreciation & Amortization
-CA$49.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-86%
|
|
Biosyent Inc
Glance View
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
See Also
What is Biosyent Inc's Depreciation & Amortization?
Depreciation & Amortization
-862.4k
CAD
Based on the financial report for Sep 30, 2025, Biosyent Inc's Depreciation & Amortization amounts to -862.4k CAD.
What is Biosyent Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-46%
Over the last year, the Depreciation & Amortization growth was -82%. The average annual Depreciation & Amortization growth rates for Biosyent Inc have been -29% over the past three years , -11% over the past five years , and -46% over the past ten years .
